G1 Therapeutics

About G1 Therapeutics

G1 Therapeutics, Inc. operates as a commercial-stage biopharmaceutical company with a clear focus on developing and commercializing small-molecule therapeutics for oncology patients. The company was founded in 2008 by Dr. Norman Sharpless, former Director of the National Cancer Institute, and Dr. Kwok-Kin Wong, spinning out of research from the University of North Carolina at Chapel Hill. Their mission centered on discovering methods to protect cancer patients from the harsh side effects of chemotherapy. After its inception as G-Zero Therapeutics, the company rebranded to G1 Therapeutics in 2012. A significant milestone was achieved on May 17, 2017, when the company went public, trading on the NASDAQ under the ticker GTHX. In a pivotal development, Danish pharmaceutical company Pharmacosmos A/S announced its acquisition of G1 Therapeutics in August 2024 for approximately $405 million, a transaction that was successfully completed in September 2024, making G1 a wholly owned subsidiary.

The company's business model is centered on the research, development, and commercialization of its primary asset, COSELA® (trilaciclib). Revenue is generated through direct product sales of COSELA and was previously supplemented by licensing and collaboration agreements. For instance, G1 had a commercialization agreement with Boehringer Ingelheim for COSELA in the U.S. and Puerto Rico and licensed development and commercialization rights to Simcere Pharmaceutical in Greater China. The primary client base consists of oncologists and healthcare providers treating patients with specific types of cancer.

G1's flagship product, COSELA (trilaciclib), is a first-in-class CDK4/6 inhibitor administered intravenously. Its key function is to decrease the incidence of chemotherapy-induced myelosuppression, a condition where bone marrow activity is suppressed, leading to lower levels of red and white blood cells and platelets. This proactive, multilineage myeloprotection helps preserve hematopoietic stem cells and immune system function during chemotherapy. The FDA approved COSELA on February 12, 2021, for adult patients with extensive-stage small cell lung cancer (ES-SCLC) receiving a platinum/etoposide-containing or topotecan-containing regimen. COSELA is administered as a 30-minute IV infusion prior to chemotherapy sessions. While the company has explored trilaciclib for other indications, such as triple-negative breast cancer and colorectal cancer, it has recently refocused its efforts primarily on the ES-SCLC market following disappointing trial results in other areas.